'A Bit of a Surprise': Kardigan's Repeat Dosing of Blood Pressure Drug Has No Benefit over Single Shot

Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC

Patients treated with tonlamarsen experienced statistically significant reductions in plasma angiotensinogen levels and

'A bit of a surprise': Kardigan's repeat dosing of blood pressure drug has no benefit over single shot

Repeat dosing of an antisense hypertension drug that Kardigan licensed from Ionis Pharmaceuticals did not lower patients’ blood pressure better than a single dose, according to Phase 2 data reported on Saturday. The KARDINAL trial ...